The CLASSIC trial tested whether restricting intravenous fluid administration after initial resuscitation would improve outcomes in adults with septic shock. More than 1,500 patients were randomised to a restrictive-fluid strategy or standard intravenous fluid therapy after receiving at least 1 litre of fluid. The restrictive group received substantially less fluid during the ICU stay, yet 90-day mortality was virtually identical between the strategies. Serious adverse events and days alive without life support were also similar. The trial is important because it challenges the assumption that simply reducing fluid volume will automatically improve survival in septic shock. At the same time, it demonstrates that clinicians can often achieve similar outcomes with much less fluid when unnecessary boluses are avoided. The practical message is therefore one of stewardship rather than blanket restriction. Fluid should be given when a patient is likely to benefit, with repeated assessment of perfusion, fluid responsiveness and the risks of overload. Once shock physiology changes, continued fluid administration can become a source of harm rather than treatment. CLASSIC fits the modern movement toward dynamic, phenotype-based resuscitation in which fluids, vasopressors and other interventions are balanced against the patient's evolving cardiovascular and organ-function profile.